Midjourney Medical Enters Healthcare: AI-Powered Full-Body Ultrasonic Scanner Generates 3D Body Maps in 60 Seconds, Targets 50,000 Units by 2031
A Cross-Industry Move into Healthcare
In June 2026, Midjourney — known for AI image generation — announced the formation of Midjourney Medical and unveiled a prototype for a full-body imaging system called Ultrasonic CT. This cross-industry move marks a new trend of AI companies entering the healthcare space and has sparked widespread industry discussion about AI technology's applications in medical diagnostics.
Technology: Water-Immersion Ultrasound Imaging
Midjourney Medical's Ultrasonic CT uses a unique water-immersion imaging approach:
How It Works
Users are lowered via an elevator into a tub of water, where a ring of sensors uses ultrasonic waves to scan the body — operating on principles similar to echolocation. This method leverages ultrasound's excellent conductivity in water to achieve high-precision full-body imaging.
Technical Foundation
The scanner relies on "ultrasound-on-chip" technology licensed from Butterfly Network under a multi-year agreement. Butterfly Network is a leading company in ultrasound chip technology, with its technology already widely used in portable ultrasound devices.
Imaging Capabilities
Midjourney Medical plans to use this hardware to generate detailed 3D maps of body composition, including muscle, fat, and organ volumes. The target scan time is 60 seconds, though current prototype scan times are longer and independent clinical validation remains pending.
Current Status and Regulatory Position
As of June 2026, Ultrasonic CT remains a first-generation prototype with important limitations:
FDA Regulatory Status
Midjourney explicitly states that the device currently does not hold FDA diagnostic clearance. Initial use is positioned for providing wellness-focused body composition data rather than medical diagnoses. The company plans to submit data to the FDA to seek expanded capabilities over time.
Technology Gaps
Medical professionals have highlighted significant gaps between the company's marketing claims and current technical capabilities:
- The advertised 60-second scan time has not been achieved on the prototype
- Claims of MRI-comparable performance lack independent clinical validation
- Ultrasound technology still has limitations in imaging accuracy for certain tissue types
Commercialization Roadmap
Despite technical challenges, Midjourney Medical has outlined an ambitious commercialization plan:
Near-Term Plans (2027)
Building a companion "Midjourney Spa" in San Francisco offering wellness services like saunas and cold plunges, expected to open in late 2027. This positioning frames Ultrasonic CT scanning as part of a premium wellness service rather than a traditional medical device.
Long-Term Goal (2031)
Plans to deploy 50,000 scanners globally. Founder David Holz has stated that the pricing goal is to make scans significantly less expensive than traditional MRI scans, improving accessibility.
AI's Role in Imaging Analysis
Midjourney Medical's core differentiation lies in applying AI image analysis capabilities to ultrasound imaging data:
Data Interpretation
AI algorithms interpret ultrasound scan data to generate 3D body composition maps, identifying the distribution and volume of muscle, fat, and organs. This process requires extensive training data and sophisticated image processing algorithms.
Personalized Health Insights
Through regular scanning, AI can track changes in individual body composition over time, providing personalized health recommendations such as tracking muscle growth and fat reduction progress.
Synergy with Midjourney's Core Capabilities
Midjourney's accumulated technical capabilities in AI image generation and understanding provide some technical foundation for entering medical imaging, though medical imaging requirements are far more stringent than artistic image generation.
Market Opportunities in Asia-Pacific
Midjourney Medical's entry has potential implications for the healthcare market in Asia-Pacific:
Preventive Medicine Demand
Asia-Pacific regions, particularly aging societies like Japan, Singapore, and South Korea, have growing demand for preventive medicine and health monitoring. Full-body composition scanning as a health management tool has potential market appeal.
Health Tech Ecosystem
The health tech ecosystems in China, Japan, Singapore, and other countries are rapidly developing, with significant market potential for AI-driven health monitoring devices.
Regulatory Challenges
Medical device regulatory frameworks vary across Asia-Pacific countries. Midjourney Medical will need to navigate different national regulatory requirements when entering APAC markets, which may be one of the main challenges in its global expansion.
Industry Impact and Controversy
Midjourney Medical's entry has sparked widespread discussion in the medical community:
Supportive Views
- AI technology has the potential to reduce medical imaging costs and improve accessibility
- Preventive health monitoring can identify health issues early
- Innovative technology pathways may break through limitations of traditional medical imaging
Skeptical Voices
- Lack of FDA clearance means it cannot be used for medical diagnosis
- The gap between technical claims and actual capabilities raises trust issues
- Medical device safety and efficacy require rigorous clinical validation
Conclusion
Midjourney Medical's Ultrasonic CT represents a typical case of an AI company entering the healthcare space. While still in the prototype stage and lacking FDA diagnostic clearance, its ambitious goal of deploying 50,000 units by 2031 and wellness-oriented market positioning demonstrate the enormous potential of AI technology in healthcare. For the Asia-Pacific healthcare market, this trend is worth watching closely, while maintaining a cautious attitude toward technical claims and awaiting independent clinical validation results.
